Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice
Por:
de Retana, SF, Marazuela, P, Sole, M, Colell, G, Bonaterra, A, Sanchez-Quesada, JL, Montaner, J, Maspoch, D, Cano-Sarabia, M, Hernandez-Guillamon, M
Publicada:
10 may 2019
Resumen:
BackgroundApoJ/clusterin is a multifunctional protein highly expressed in the brain. The implication of ApoJ in -amyloid (A) fibrillization and clearance in the context of Alzheimer's disease has been widely studied, although the source and concentration of ApoJ that promotes or inhibits A cerebral accumulation is not clear yet. ApoJ is abundant in plasma and approximately 20% can appear bound to HDL-particles. In this regard, the impact of plasmatic ApoJ and its lipidation status on cerebral -amyloidosis is still not known. Hence, our main objective was to study the effect of a peripheral increase of free ApoJ or reconstituted HDL particles containing ApoJ in an experimental model of cerebral -amyloidosis.MethodsFourteen-month-old APP23 transgenic mice were subjected to subchronic intravenous treatment with rHDL-rApoJ nanodiscs or free rApoJ for 1month. A concentration and distribution in the brain, as well as A levels in plasma and CSF, were determined after treatments. Other features associated to AD pathology, such as neuronal loss and neuroinflammation, were also evaluated.ResultsBoth ApoJ-based treatments prevented the A accumulation in cerebral arteries and induced a decrease in total brain insoluble A(42) levels. The peripheral treatment with rApoJ also induced an increase in the A(40) levels in CSF, whereas the concentration remained unaltered in plasma. At all the endpoints studied, the lipidation of rApoJ did not enhance the protective properties of free rApoJ. The effects obtained after subchronic treatment with free rApoJ were accompanied bya reduction in hippocampal neuronal loss and an enhancement of the expression of aphagocytic marker in microglial cells surrounding A deposits. Finally, despite the activation of this phagocytic phenotype, treatments did not induce a global neuroinflammatory status. In fact, free rApoJ treatment was able to reduce the levels of interleukin-17 (IL17) and keratinocyte chemoattractant (KC) chemokine in the brain.ConclusionsOur results demonstrate that an increase in circulating human rApoJ induces a reduction of insoluble A and CAA load in the brain of APP23mice. Thus, our study suggests that peripheral interventions, based on treatments with multifunctional physiological chaperones, offer therapeutic opportunities to regulate the cerebral A load.
Filiaciones:
de Retana, SF:
Univ Autonoma Barcelona, Vall dHebron Res Inst, Neurovasc Res Lab, Barcelona 08035, Spain
Marazuela, P:
Univ Autonoma Barcelona, Vall dHebron Res Inst, Neurovasc Res Lab, Barcelona 08035, Spain
Sole, M:
Univ Autonoma Barcelona, Vall dHebron Res Inst, Neurovasc Res Lab, Barcelona 08035, Spain
Colell, G:
Univ Autonoma Barcelona, Vall dHebron Res Inst, Neurovasc Res Lab, Barcelona 08035, Spain
Bonaterra, A:
Univ Autonoma Barcelona, Vall dHebron Res Inst, Neurovasc Res Lab, Barcelona 08035, Spain
Sanchez-Quesada, JL:
Hosp St Pau IIB St Pau, Cardiovasc Biochem Grp, Res Inst, Barcelona, Spain
ISCIII, CIBER Diabet & Metab CIBERDEM, Madrid, Spain
Montaner, J:
Univ Autonoma Barcelona, Vall dHebron Res Inst, Neurovasc Res Lab, Barcelona 08035, Spain
Maspoch, D:
CSIC, Catalan Inst Nanosci & Nanotechnol ICN2, Campus UAB, Barcelona, Spain
Barcelona Inst Sci & Technol, Campus UAB, Barcelona, Spain
ICREA, Barcelona 08100, Spain
Cano-Sarabia, M:
CSIC, Catalan Inst Nanosci & Nanotechnol ICN2, Campus UAB, Barcelona, Spain
Barcelona Inst Sci & Technol, Campus UAB, Barcelona, Spain
ICREA, Barcelona 08100, Spain
Hernandez-Guillamon, M:
Univ Autonoma Barcelona, Vall dHebron Res Inst, Neurovasc Res Lab, Barcelona 08035, Spain
Gold, Green Published
|